Myriad Genetics to sell prenatal testing business to Labcorp
MYGN•Myriad Genetics will sell its prenatal health testing business to Labcorp for $210 million in cash plus inventory. Labcorp expects the deal to add $160 million in revenue and be slightly accretive to adjusted earnings in year one; closing is expected by early 2027, pending regulatory clearance.
1. Deal terms
Myriad Genetics and Labcorp agreed to the sale of Myriad’s prenatal health testing business for $210 million in cash plus inventory. Labcorp expects the deal to add $160 million in revenue and be slightly accretive to adjusted earnings in its first year.
2. Expected closing
The deal is expected to close by early 2027, pending regulatory clearance.
